Record quarterly revenues rose 16% year-over-year, driven by strong global patient growth and new product launches. Gross margin improved to 78%, and full-year guidance was raised, reflecting confidence in continued expansion and operational progress.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.